Research programme: pyrrolobenzodiazepine based therapeutics - Pivot Pharmaceuticals

Drug Profile

Research programme: pyrrolobenzodiazepine based therapeutics - Pivot Pharmaceuticals

Alternative Names: PVT 005; PVT 006

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IndUS Pharmaceuticals
  • Developer Pivot Pharmaceuticals
  • Class Benzodiazepines; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Endometrial cancer; Sexual function disorders

Most Recent Events

  • 27 Jun 2018 Pivot Pharmaceuticals announces intention to submit IND application to US FDA and CTA to Health Canada for clinical trials in Sexual function disorders in women
  • 30 Mar 2017 Pivot Pharmaceuticals receives patent allowance from USPTO for pyrrolobenzodiazepine dimer (PBD) drugs
  • 30 Dec 2015 Preclinical trials in Breast cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top